A Prospective Study of a Mosaic Embryo Transfer to Investigate Clinical Outcomes After IVF With Genetic Testing

What this Trial Is About

Researchers are investigating the outcomes after transferring a mosaic embryo, which contains both normal and abnormal chromosomal cells, in women undergoing in vitro fertilization (IVF) with preimplantation genetic testing (PGT). This prospective study aims to understand if transferring these embryos results in successful pregnancies and healthy live births, as some studies have suggested. The research focuses on implantation rates and live birth rates to determine if mosaic embryos should be routinely offered for transfer to patients experiencing infertility. Participants will undergo a single transfer of a mosaic embryo to the uterus after completing an IVF cycle with PGT at the Colorado Center for Reproductive Medicine. PGT involves testing a small number of cells from the embryo before transfer. Embryos identified as mosaic are usually not transferred as standard practice, but this study evaluates their potential for successful pregnancy. The study does not use a placebo or comparison group. Women in the study will be monitored through multiple follow-up periods after embryo transfer. Researchers will assess implantation rates 3 to 4 weeks after transfer and track live birth rates up to 9 to 12 months later. Additional outcomes include miscarriage rates, pregnancy complications, stillbirth rates, prenatal testing results, and neonatal outcomes up to 15 months after birth. Participants will have various clinical evaluations and tests as part of their routine care during the study period, which lasts up to about a year after embryo transfer.

A Prospective Study of a Mosaic Embryo Transfer